创新药板块飙升，恒生创新药ETF(159316)标的指数涨超2%，各地支持政策密集出台

Core Viewpoint - The Hong Kong innovative drug sector is experiencing a significant rise, driven by supportive government policies and a focus on high-quality development in the pharmaceutical industry [1][2]. Group 1: Market Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 2.0% as of 11:05 AM, with notable gains in stocks such as InnoCare Pharma-B, which increased by over 7%, and Lepu Biopharma-B, Innovent Biologics, and 3SBio, each rising by over 4% [1]. - The Hang Seng Innovative Drug ETF (159316) recorded a trading volume of nearly 400 million yuan [1]. Group 2: Policy Support - Xi'an has released the "Implementation Plan for Promoting the Capacity Enhancement of the Biopharmaceutical Industry (2025-2027)," aiming to achieve breakthroughs in key drug development technologies in areas such as stem cell drugs, peptide drugs, liver-targeted innovative drugs, and anesthetics [1]. - Various regions, including Beijing, Shanghai, Chongqing, and Sichuan, have introduced policies this year to promote high-quality development in the innovative drug sector [1]. Group 3: Industry Outlook - Changjiang Securities notes that the pharmaceutical industry is experiencing a policy cyclical trend, with comprehensive support policies for the innovative drug industry being gradually implemented [1]. - The industry is entering a new cycle of policy support, with a focus on "hard innovation" assets and those with strong overseas potential [1].